News
-
-
-
COMMUNIQUÉ DE PRESSE
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
NanoViricides, Inc. announces Phase II Clinical Trial of NV-387 Oral Gummies for Ebola viruses led by Prof. Patrick Katoto in DRC. Trial response to growing Bundibugyo outbreak -
-
-
COMMUNIQUÉ DE PRESSE
Elmos Semiconductor SE: Extraordinary General Meeting elects new members to the Supervisory Board
Elmos Semiconductor SE's Extraordinary General Meeting elects new members to the Supervisory Board, ensuring generational transition. Strategic objectives and corporate governance key focus -
-
COMMUNIQUÉ DE PRESSE
Lobe Sciences Reports Third Quarter 2026 Financial Results
Lobe Sciences Ltd. announces unaudited financial results for Q3 2026, showing progress in R&D and capital allocation. Equity position increased. Private placements closed and announced. Subsidiaries focusing on drugs for neurological and psychiatric disorders -
COMMUNIQUÉ DE PRESSE
FORT Robotics to Go Public via Business Combination with Newbury Street II Acquisition Corp to Advance the Safety of Physical AI
FORT Robotics to go public via business combination with Newbury Street II Acquisition Corp, creating the first publicly traded company dedicated to safe deployment of physical AI across industries -
![Logo de [UNKNOWN]](https://logos.symex.be/img/.jpg)
